HIV/AIDS Topics CROI 2013: Second-line NRTI-sparing HIV Regimen Proves Equally Effective
- Details
- Category: HIV Treatment
- Published on Wednesday, 20 March 2013 00:00
- Written by Keith Alcorn
A second-line antiretroviral regimen of lopinavir/ritonavir (Kaletra or Aluvia) and raltegravir (Isentress) proved just as effective as a regimen containing lopinavir/ritonavir and 2 or 3 nucleoside or nucleotide analogs in large study conducted in Australia, Africa, Latin America, and Asia, researchers from Sydney’s Kirby Institute reported this week at the 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013) in Atlanta.
CROI 2013: Small Risk of Birth Defects Due to Efavirenz Confirmed in French Cohort
- Details
- Category: HIV Treatment
- Published on Wednesday, 20 March 2013 00:00
- Written by Keith Alcorn
A large French study has found an elevated risk of some birth defects in children born to women exposed to some antiretroviral drugs during the first trimester of pregnancy, French researchers reported on at the 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013) this month in Atlanta.
CROI 2013: Can HIV Elite Controllers Benefit from Antiretroviral Treatment?
- Details
- Category: HIV Treatment
- Published on Friday, 15 March 2013 00:00
- Written by Liz Highleyman
Elite controllers -- people who naturally maintain undetectable viral load without antiretroviral therapy (ART) -- experienced decreased levels of HIV genetic material and reductions in markers of inflammation and immune activation after starting experimental treatment, according to study findings presented at the 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013) last week in Atlanta.
CROI 2013: MK-1439 -- A Novel NNRTI For HIV Treatment [VIDEO]
- Details
- Category: HIV Treatment
- Published on Friday, 15 March 2013 00:00
- Written by Gregory Fowler
A next-generation non-nucleoside reverse transcriptase inhibitor (NNRTI), MK-1439, demonstrated good antiretroviral activity and tolerability as 7-day monotherapy in a small Phase 1b trial, researchers reported at the 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013) last week in Atlanta.
CROI 2013: Zinc Finger Gene Therapy Leads to Durable T-Cell Recovery, Sangamo Says
- Details
- Category: Search for a Cure
- Published on Monday, 11 March 2013 00:00
- Written by Liz Highleyman
Modification of CD4 T-cells using zinc finger technology designed to render cells resistant to HIV led to durable immune reconstitution, while a different gene therapy technique may make cells less susceptible to viral infection, according to 2 studies presented at the 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013) last week in Atlanta.
CROI 2013: Challenges and Opportunities for the Development of Long-acting Antiretrovirals [VIDEO]
- Details
- Category: HIV Treatment
- Published on Friday, 15 March 2013 00:00
- Written by Gregory Fowler
Marta Boffito from Chelsea and Westminster Hospital in London presented an overview of some of the challenges and opportunities in the development of long-acting antiretroviral agents for HIV treatment and prevention in a themed discussion at the 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013) last week in Atlanta.
CROI 2013: Early Antiretroviral Therapy May Reduce HIV Reservoir Size [VIDEO]
- Details
- Category: Search for a Cure
- Published on Monday, 11 March 2013 00:00
- Written by Gregory Fowler
Starting antiretroviral therapy (ART) very early may restrict the size of the established HIV reservoir in long-lived T-cells, which could ultimately make it easier to achieve a functional cure, according to research presented last week at the 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013) in Atlanta.
More Articles...
- CROI 2013: Dolutegravir Helps Highly-resistant Treatment-experienced People on Failing ART
- CROI 2013: New Antiretroviral Agents: Cenicriviroc [VIDEO]
- CROI 2013: New Pro-drug Tenofovir Alafenamide Appears Equally Effective but Better Tolerated
- CROI 2013: Can People with Resistant HIV Omit NRTIs When Switching to a New Regimen? [VIDEO]
- CROI 2013: HIV Treatment for Children Safe and Highly Effective without Laboratory Monitoring
Web Design and Development by